News Release 2018
-
- December 27, 2018
- Hebrew University to Collaborate with KYORIN Strategic partnership aims to develop respiratory drug therapies
-
- November 20, 2018
- Launch of "Beova® Tablets 50mg" for the Treatment of Overactive Bladder
-
- November 5, 2018
- Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2018) [Japanese Standard]
-
- November 5, 2018
- Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2019
-
- November 5, 2018
- Notice Regarding the Cancellation of Treasury Stock
-
- November 2, 2018
- Revision of Consolidated Financial Forecasts
-
- September 27, 2018
- Notice on Results and Completion of Acquisition of Treasury Stock through Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3) and Change to Major Shareholder
-
- September 26, 2018
- Notice of Acquisition of Treasury Stock and Purchase of Treasury Stock by Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3)
-
- September 21, 2018
- Kyorin Receives Marketing Approval in Japan for｢Beova Tablets 50mg｣ for the Treatment of Overactive Bladder
-
- August 6, 2018
- (Corrections: Corrections of Numeric Data) On the Partial Correction of the Summary Accounts of the First Quarter of the Business Year Ending in March 2019 [Japanese Standard] (Consolidated)
-
- August 1, 2018
- KYORIN Pharmaceutical and FAES Farma Sign Agreement on Development and Distribution of Imidafenacin in Latin America
-
- July 31, 2018
- Summary of Consolidated Financial Results（July 31, 2018)
-
- July 31, 2018
- Supplementary information (July 31, 2018)
-
- July 31, 2018
- Changes in Capital Policy and Shareholder Return Policy
-
- July 31, 2018
- Revision of Dividend Forecast in Fiscal Year ended March 31, 2019
-
- May 10, 2018
- Summary of consolidated financial results (May 10, 2018)
-
- May 10, 2018
- Supplementary information (May 10, 2018)
-
- May 10, 2018
- MSD and Kyorin Sign Agreement to Acquires Exclusive Distribution Rights for Therapeutic Agent for Allergic Rhinitis, NASONEX® Nasal
-
- March 29, 2018
- Kyorin Pharmaceutical Sign a License Agreement for "SK-1404," a Therapeutic Agent for Nocturia Due to Nocturnal Polyuria
-
- February 5, 2018
- Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2017)［Japanese Standard］
-
- February 5, 2018
- Consolidated Financial Results (For the third Quarter Ended Dec 31,2017)- Supplementary Information
